Investor Overview

Corporate Profile

HTG Molecular Diagnostics, Inc's. (“HTG”) mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary target protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG Edge chemistry and automation with NGS technology. The HTG EdgeSeq system enables fast and easy use of NGS instruments for molecular profiling.

Stock Quote

HTGM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.76
Change (%)0.00 (0.00%)
Volume1,300
Data as of 05/22/17 4:00 p.m. ET

Recent News

05/15/17
HTG Molecular Diagnostics Reports First Quarter 2017 Results
05/04/17
HTG Molecular Diagnostics Introduces HTG EdgeSeq PATH Assay to Launch in Second Quarter 2017
05/01/17
HTG Molecular Diagnostics to Hold 2017 First Quarter Results Conference Call on May 15, 2017
04/24/17
HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration
More News >>

Upcoming Events

There are currently no events scheduled.
More Events >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Shareholder Tools

Print Page Print Page   E-mail Page E-mail Page   RSS Feeds RSS Feeds   E-mail Alerts E-mail Alerts